Transferrin Receptor-Targeted Iduronate-2-sulfatase Penetrates the Blood-Retinal Barrier and Improves Retinopathy in Mucopolysaccharidosis II Mice
Molecular Pharmaceutics · 2023
DOI: 10.1021/acs.molpharmaceut.3c00736 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2023. Verfasst von Atsushi Imakiire und 13 weiteren Autor:innen. Beteiligte Einrichtung: Research Division, JCR Pharmaceuticals, 1-5-4 Murotani, Nishi-ku, Kobe 651-2241, Japan. Hauptthemen laut MEDLINE: Iduronate Sulfatase, Mucopolysaccharidosis II, Retinal Diseases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JCR Pharmaceuticals.
Abstract (Originalsprache)
Mucopolysaccharidoses (MPSs) make up a group of lysosomal storage diseases characterized by the aberrant accumulation of glycosaminoglycans throughout the body. Patients with MPSs display various signs and symptoms, such as retinopathy, which is also observed in patients with MPS II. Unfortunately, retinal disorders in MPS II are resistant to conventional intravenous enzyme-replacement therapy because the blood-retinal barrier (BRB) impedes drug penetration. In this study, we show that a fusion protein, designated pabinafusp alfa, consisting of an antihuman transferrin receptor antibody and iduronate-2-sulfatase (IDS), crosses the BRB and reaches the retina in a murine model of MPS II. We found that retinal function, as assessed by electroretinography (ERG) in MPS II mice, deteriorated with age. Early intervention with repeated intravenous treatment of pabinafusp alfa decreased heparan sulfate deposition in the retina, optic nerve, and visual cortex, thus preserving or even improving the ERG response in MPS II mice. Histological analysis further revealed that pabinafusp alfa mitigated the loss of the photoreceptor layer observed in diseased mice. In contrast, recombinant nonfused IDS failed to reach the retina and hardly affected the retinal disease. These results support the hypothesis that transferrin receptor-targeted IDS can penetrate the BRB, thereby ameliorating retinal dysfunction in MPS II.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Division, JCR Pharmaceuticals, 1-5-4 Murotani, Nishi-ku, Kobe 651-2241, Japan.
ORCID-Profile: Kohtaro Minami
Förderung
- JCR Pharmaceuticals
Zitieren
APA
Imakiire, A., Morimoto, H., Suzuki, H., Masuda, T., Yoden, E., Inoue, A., Morioka, H., Konaka, T., Mori, A., Shirasaka, R., Kato, R., Hirato, T., Sonoda, H., & Minami, K. (2023). Transferrin Receptor-Targeted Iduronate-2-sulfatase Penetrates the Blood-Retinal Barrier and Improves Retinopathy in Mucopolysaccharidosis II Mice. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.3c00736
Vancouver
Imakiire A, Morimoto H, Suzuki H, Masuda T, Yoden E, Inoue A, et al. Transferrin Receptor-Targeted Iduronate-2-sulfatase Penetrates the Blood-Retinal Barrier and Improves Retinopathy in Mucopolysaccharidosis II Mice. Molecular Pharmaceutics. 2023. doi:10.1021/acs.molpharmaceut.3c00736
BibTeX
@article{Imakiire2023,
author = {Imakiire, Atsushi and Morimoto, Hideto and Suzuki, Hidehiko and Masuda, Tomomi and Yoden, Eiji and Inoue, Asuka and Morioka, Hiroki and Konaka, Takashi and Mori, Ayaka and Shirasaka, Ryoji and Kato, Ryo and Hirato, Tohru and Sonoda, Hiroyuki and Minami, Kohtaro},
title = {Transferrin Receptor-Targeted Iduronate-2-sulfatase Penetrates the Blood-Retinal Barrier and Improves Retinopathy in Mucopolysaccharidosis II Mice},
journal = {Molecular Pharmaceutics},
year = {2023},
doi = {10.1021/acs.molpharmaceut.3c00736}
}
EUVIMED